Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
|Articles|August 1, 2018
- Pharmaceutical Executive-08-01-2018
- Volume 38
- Issue 8
Pharmaceutical Executive, August 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Emerging Biotech: Innovation, Location, and Inspirationabout 8 years ago
Cross-Border Funding in the Life Sciencesabout 8 years ago
Face It. You’re Not a Biotech Anymoreabout 8 years ago
The Pulse of Biopharma M&Aabout 8 years ago
The Big Apple’s Fresh Start in Biotechabout 8 years ago
‘Emerging’ Product Launch Strategiesabout 8 years ago
Biotech Investment: Reigning in Spainabout 8 years ago
Traditional Scientific Search is Brokenabout 8 years ago
Tough Fight Looms in Preserving R&D Incentivesabout 8 years ago
From Science to SuccessAdvertisement
Related to this article
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
5